Advantages and Challenges of PRM Technology in Quantifying Low Abundance Proteins

In proteomics research, precise quantification of low-abundance proteins is crucial for early disease biomarker discovery, drug target validation, and complex signal pathway analysis. However, conventional Data-Dependent Acquisition (DDA) methods often face challenges such as insufficient detection sensitivity and poor reproducibility when dealing with complex sample backgrounds and extremely low-abundance target molecules. In recent years, PRM technology (Parallel Reaction Monitoring) has gained widespread attention in targeted low-abundance protein quantification due to its high selectivity, high reproducibility, and high throughput characteristics. This article will systematically analyze the technical advantages and real-world challenges of PRM in low-abundance protein detection and share Betta Park BioTech's application experience and technical platform in this field.

 

I. Overview of PRM Technology: Evolution from SRM to PRM

PRM technology is a high-resolution targeted mass spectrometry technique developed from traditional Selected Reaction Monitoring (SRM/MRM). Its core principle is to monitor all fragment ions of the target peptide continuously on high-resolution Orbitrap or TOF mass spectrometers, thereby improving quantification accuracy and specificity.

 

II. Advantages and Challenges of PRM Technology in Quantifying Low-Abundance Proteins

PRM is a targeted quantification method based on high-resolution mass spectrometry platforms such as Orbitrap. Its workflow includes selecting specific precursor ions through an LC-MS system, followed by full-scan acquisition of all their fragment ions. During data processing, researchers can freely choose the most representative ions for quantification based on the fragment spectra, enhancing the method's flexibility and specificity.

 

1. Key advantages include:

(1) High resolution and mass accuracy: The Orbitrap system can offer ppm-level mass precision, significantly enhancing the ability to identify target ions.

(2) No need to predefine transition ions: Unlike SRM, PRM technology allows for flexible post-analysis selection of fragments used for low-abundance protein quantification, improving analytical depth and result robustness.

(3) Suitable for complex matrix samples: High selectivity helps reduce background interference, especially suitable for samples with high dynamic ranges like plasma and cerebrospinal fluid.

 

2. While PRM has inherent advantages, it still faces multiple technical bottlenecks in low-abundance protein quantification:

(1) Poor response of target peptides: Some protein peptides inherently have low ionization efficiency, are easily inhibited by the matrix, and struggle to form stable signals.

(2) Sample complexity interferes with detection: Protein concentrations in plasma span 12 orders of magnitude, and signals from target peptides are easily masked by high-abundance proteins.

(3) Limitations in reproducibility and linear range: Achieving stable detection across batches and samples at concentrations below femtomoles (fmol) requires highly optimized analytical conditions and strict quality control.

(4) High complexity of data analysis: Although tools like Skyline offer good visualization, high-quality data interpretation still relies on experienced mass spectrometry analysts, especially when background interference is significant.

 

Betta Park BioTechIntegrates the Orbitrap Exploris 480 high-resolution mass spectrometry system with deeply optimized targeted proteomics workflows to provide sensitive, accurate, and reproducible PRM quantification services for research and clinical translation. Betta Park BioTech integrates the entire process capability of target design, method development, sample processing, and data analysis. We have specially developed high-sensitivity PRM quantification workflows for low-abundance proteins, applicable to:

• Disease-related biomarker validation (such as early-stage tumors and neurodegenerative diseases)

• Dynamic tracking of targets in drug efficacy evaluation and mechanism research

• Standardized PRM analysis in multi-center clinical samples

PRM technology offers the possibility of high-sensitivity detection for low-abundance protein quantification, showing great potential especially in biomarker validation and preclinical research. In the future, with further integration of mass spectrometry technology and data algorithms, PRM will play a more central role in precision medicine. Betta Park BioTech will continue to promote the application of this cutting-edge technology, injecting more possibilities into life science research.

 

Betta Park BioTech—A quality service provider in biological product characterization and multi-omics biomolecule mass spectrometry detection

 

Related services:

Parallel Reaction Monitoring (PRM) Services